Summary
| Direction in Epilepsy | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Other |
| Compared against | drug-responsive, well-controlled seizures and healthy controls |
| Source | Walker et al. 2022 — doi:10.1111/epi.17116 |
| Condition atlas | Epilepsy Biomarker Atlas |
Related Other markers in Epilepsy
Full list: Epilepsy Biomarker Atlas.
Frequently asked questions
Is High-Mobility Group Box 1 (HMGB1) high or low in Epilepsy?
Elevated. Studies summarised in the OSMF atlas report higher High-Mobility Group Box 1 (HMGB1) in Epilepsy than in drug-responsive, well-controlled seizures and healthy controls. Source: Walker et al. 2022.
Which test measures High-Mobility Group Box 1 (HMGB1)?
The atlas record does not list a standardised clinical test code (LOINC) for High-Mobility Group Box 1 (HMGB1), which usually means it was measured with research assays or study-specific protocols rather than a routine clinical panel. Check the cited source for the exact method.
Is one abnormal High-Mobility Group Box 1 (HMGB1) result diagnostic of Epilepsy?
No. No single biomarker is diagnostic of Epilepsy. High-Mobility Group Box 1 (HMGB1) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Subscribe on Substack
Last reviewed: 2026-10-08 · Page generated from epilepsy.json · Browse: Epilepsy atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.